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Athlete’s Foot: A Disease of Fitness
and Hygiene
In May 1939, a review of the American yearbook of dermatology and
syphilology observed:
As usual they make a prominent feature of an introductory article
on some branch of therapeutics, and this year they deal with the
treatment of the deeper fungous infections of the skin, including
ringworm of the scalp and bearded regions, and the comparatively
rare fungous affections of the subcutaneous tissues. As a matter of fact
this subject is not of great practical importance in the British Isles,
especially in England, where the incidence of ringworm of the scalp
has been reduced to quite a trivial number of cases per annum, and
ringworm of the beard has become an actual rarity. No doubt the state
of affairs is otherwise in the United States, where the standard of liv-
ing, both among the large negro population and also to a lesser extent
among the more recent immigrants from Central Europe, is such that
these infections are much commoner; moreover, a considerable area
of the U.S.A. boasts a subtropical climate in which parasitic fungi are
far more active than in the temperate zones.1
While this statement rightly reﬂects on improvements in Britain, its per-
ception of ringworm in the United States was wrong. Across the Atlantic,
it was not a problem amongst immigrants and African Americans; rather
it had been framed as a public health menace in the afﬂuent classes,
especially amongst those who frequented swimming pools, and college
students and, of course, athletes. While its prevalence had seemingly
shifted up the social scale and from children to adults, its principal site
of infection had moved too, from head to toe, with ‘athlete’s foot’ being
one of the most common and most talked about diseases in America in
the 1930s.2
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Manufacturers of popular remedies gave ringworm of the foot the
name ‘athlete’s foot’ and this was adopted by the public, but in medicine
the infection was known as tinea pedis. It was seen as new disease, or in
modern parlance an emerging infection, having been ﬁrst described by
Arthur Whitﬁeld, a dermatologist at King’s College Hospital, London in
1908.3 Nonetheless, it was in the United States that tinea pedis became
an epidemic, seemingly spread by modern lifestyles and hygiene prac-
tices, and encouraged by modern socks and shoes, which made infection
liable to chronicity by keeping the feet moist and warm. It is perhaps
surprising, given the unhygienic conditions of previous centuries and
the ubiquity of ringworm of the scalp, that the feet of Europeans and
Americans had been seemingly free of ringworm infection until the
mid-twentieth century. Nonetheless, there was a clear understanding
in the inter-war years that tinea pedis was new disease and one linked
to modernity. One consequence of the growth of medical attention to
tinea pedis was the stimulus it gave to the specialism of medical mycol-
ogy, with investment in diagnostic services, research on the conditions
in which mycoses spread and their treatment. In turn, this led to the
creation of a cadre of medical mycologists, who identiﬁed more fungal
infections in speciﬁc social groups and the general population.
We begin this chapter with a discussion of the development of med-
ical mycology, especially in the United States, which led the world in
the creation of centres of expertise, training and research. We then dis-
cuss the movement of medical and public concern about ringworm from
children’s heads to athlete’s toes. In the 1940s, the condition was also
recognised as a problem amongst soldiers and miners, and was seen in
terms of greater exposure to new pathogenic species of fungi and the
increased vulnerability of the human soil in tropical and speciﬁc work
conditions. While orthodox medicine approached tinea pedis as some-
thing that was difﬁcult to treat and needed to be prevented, proprietary
medicine companies peddled remedies that ﬁlled the therapeutic vac-
uum with numerous ‘certain cures’. We follow the controversies around
popular and medical treatments, and the emergence in the late 1950s
of medically approved, clinically trialled antifungal drugs, modelled on
the antibiotics developed for bacterial infections. The most important
of these was griseofulvin, which promised to be effective and safe with
topical and oral administration. This was followed in the 1970s with a
range of azole drugs. These antifungals accelerated the disappearance of
athlete’s foot as a medical, if not public term, thereby divorcing ring-
worm from its locus of infection or site of contagion, making it a type
of dermatophytosis, literally, skin fungal infection.
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Medical mycology: ‘An Orphan Science’4
Glenn S. Bulmer has recently characterised the manner in which work
on human fungal diseases developed in the inter-war period as the
result of the movement and coalescence of specialists: ‘botany types
came forth and usually joined Departments of Microbiology &/or
Immunology – two subjects that most had never taken in school’.5
He may have had in mind the founders of the ﬁrst specialist medical
mycology laboratory in the United States, which opened in 1926 at the
Columbia-Presbyterian Medical Center (C-PMC). One leading light was
the botanist was Bernard O. Dodge, who then worked at the New York
Botanical Gardens.6 He was known for his work on genetics and for
introducing T. H. Morgan to Neurospora, an organism that became a
widely used experimental model in genetics.7 Dodge was interested in
fungal diseases in humans and animals, and between 1928 and 1939
he was a consultant in mycology at the C-PMC, while at the same time
lecturing on dermatology at the College of Physicians and Surgeons.
The other founder as a clinician, the dermatologist J. Gardner Hopkins,
who worked at the C-PMC’s Vanderbilt Clinic; previously he had worked
on a cure for the plague with Hans Zinsser in Serbia during the First
World War.8 Indeed, his research spanned infectious diseases, especially
syphilis and moniliasis. In the 1920s and 1930s it was mainly ‘botany
types’, with the ability to identify types of fungi, who dominated the
new ﬁeld, which was principally concerned with diagnosis, requiring
microscopy and culturing skills, combined with taxonomy. In 1926,
Hopkins hired Rhoda W. Benham – a botanist by training – to undertake
mycological diagnoses, and went on to develop a research laboratory
from this base.9 His initiative was aided by a grant of $50,000 from the
Rockefeller Foundation in 1929, which eventually enabled Columbia to
develop the ﬁrst specialist training in human fungal diseases in 1935.
Hopkins’s laboratory became an inﬂuential research centre, producing
key ﬁgures such as Chester W. Emmons (1900–1985), the ﬁrst medi-
cal mycologist employed by the National Institutes of Health (NIH) in
Bethesda.10 Emmons took his PhD with Robert A. Harper in the Botany
Department at Columbia on the subject of mildew, before working
with Dodge and publishing two articles on dermatophytes in Archives
of Dermatology and Syphilis. Neither author was medically qualiﬁed.
Emmons stated later that when he sought a reference to move to Hop-
kins’s laboratory, Harper had asked, ‘Why do you want to study those
abortive and uninteresting medical fungi?’11 Indeed, Emmons referred
to medical mycology as ‘an orphan science’ as it was never taught by
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mycologists, whose main interest, outside of taxonomy, reproduction
and other purely biological matters, was in plant pathology. In his ﬁrst
medical publications, Emmons proposed redeﬁning the genera of the
main fungal causes of skin infection: Microsporum, Trichophyton and Epi-
dermophyton. His approach was to use their morphologies, rather than
their pathological effects, pioneering what became the preferred method
of standardising diagnoses and avoiding the variability and inconsis-
tency of clinical criteria.12 Emmons then worked with Arturo Carrión
in Puerto Rica on chromoblastomycosis, publishing in the Puerto Rico
Journal of Public Health and Tropical Medicine. In the event, the move to
fungal diseases turned out well, as his appointment at NIH was as prin-
cipal mycologist. He stayed for 30 years, becoming recognised as one of
‘founding fathers’ of medical mycology in the United States.
The ﬁrst monograph in the ﬁeld was Harry Jacobson’s Fungous
Diseases: A Clinico-Mycology Text published in 1932. The author was
a dermatologist in Los Angeles and he presented ten chapters on
‘dermomycoses, moniliasis, maduromycoses, sporotrichoses, blasto-
mycoses, actinomycoses, coccidioides, toruloses and aspergilloses’.13
A review in Archives of Dermatology concluded that the book was ‘use-
ful’ and, perhaps surprisingly, observed that ‘the mycologic aspects of
the subject are better handled than the clinical aspects’. The second
monograph was published from Harvard, where there had been instruc-
tion since 1924, and it was this course that was written up in 1935 by
Carroll W. Dodge, a botanist who was no relation of Bernard O. Dodge.14
The book was compiled at the suggestion of Roland Thaxter, who was
medically trained, but had switched to botany, eventually becoming
professor of cryptogamic botany at Harvard. Carroll Dodge’s Medical
Mycology: Fungous Diseases of Man and Other Animals was the ﬁrst use of
‘medical mycology’ in a book title. Here, and in later works, the primary
focus was on fungi and their identiﬁcation, with little on the pathol-
ogy of the infections they caused. Before publication, Dodge had moved
to become professor of botany at Washington University and contin-
ued to research fungal diseases in Central America, before moving to
Lichenology after 1950.
Writing the New England Journal of Medicine in August 1936, Jacob
H. Swartz, of the Department of Cryptogamic Botany at Harvard Uni-
versity, maintained that,
Mycology is no longer a mysterious subject known only to a few.
It has been proved to be a part of medicine just as bacteriology, phys-
iology and so forth. Some knowledge of mycology is necessary for a
better understanding of disease.15
Athlete’s Foot: A Disease of Fitness and Hygiene 47
He was contributing to a discussion on fungi and internal medicine,
where the focus was not on skin diseases, but on systemic infections
and allergy, with an emphasis on the importance of predisposition – the
human soil – as a factor with infection. Many contributors stressed the
role of the laboratory in conﬁrming clinical diagnoses; though Swartz
worried that since the ‘mystery’ of fungi had been largely solved, clin-
icians were no longer turning to the laboratory and were relying solely
on clinical signs. The ‘orphan science’ had been adopted by doctors, but
it was not being nurtured. Swartz closed the discussion demanding the
creation of a mycological department in every medical school and hos-
pital, stating that ‘Mycology at present is in chaos’ and calling for the
ﬁeld to be ‘simpliﬁed and made useful to all branches of medicine’.16
Arthur Greenwood, a dermatologist at Massachusetts General Hospital,
suggested the way forward was to create more people trained to work
between clinicians and mycologists.17 One factor fuelling the demand
for more medical mycologists, reﬂected in the discussion prompted by
Swartz, was recognition of geographically localised foci of fungal disease,
which we examine in Chapter 4. Meanwhile, athlete’s foot or tinea pedis
was emerging as a dominate concern for dermatologists and nascent
medical mycologists.
Athlete’s foot
Infection in areas other than the scalp came to the fore in the First
World War, when ringworm of the groin (‘dhobi itch’) was found to be
prevalent amongst American and British troops in France.18 Some doc-
tors thought that damp and crowded conditions of the Western Front
increased susceptibility and were ideal for contagion; others believed a
new fungus had been brought to Europe and the Americas by troops
returning from the tropics.19 The bacteriological facilities available to
the military medical services meant that speciﬁc pathogens were iden-
tiﬁed, using the methods developed by Sabouraud in the 1900s. Most
cases were of Trichophyton interdigitalis, but there were increasing reports
of Trichophyton rubrum, though at this time there was little interest in
the epidemiology of types of infection.20 Rather, discussion focused on
the observation that, paradoxically, tinea pedis was a disease of hygiene.
In the British military, the highest rates of infection were found amongst
ofﬁcers, who through bathing regularly opened themselves to infection
through contact and softening of the skin. Also, tightly laced, ankle-
high army boots, worn in hot, damp environments, for long periods
without changes of socks, were understood to provide ideal conditions
for tinea pedis to ﬂourish.21
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In the United States too, ringworm of the feet was ‘discovered’ as a
malady of soldiers in the First World War. Two West Coast American
doctors, Oliver Ormsby and James Mitchell, put ringworm of the feet
on the medical map in the United States in 1916, in an article on infec-
tion of the hands and feet.22 The alleged ﬁrst use of the term ‘athlete’s
foot’ was in December 1928, in an article in the Literary Digest, prompted
by reports from Dr Charles F. Pabst, of Greenpoint Hospital Brooklyn.23
Pabst claimed that the condition was already well-known in the United
States, with an estimated ten million sufferers, three quarters of whom
were unaware of the infection. The article stated that the problem was of
recent origin, but that ‘at least half the adult population suffer from this
malady at some time’. However, the term athlete’s foot took hold, not
as a disease of the masses, but one of the America’s afﬂuent classes, who
could now afford to enjoy leisure activities and modern hygiene facil-
ities. Pabst, perhaps revealing his limited social circle and awareness,
claimed that ‘almost everyone who uses a swimming-pool, golf club,
athletic club, or any place where there is a common dressing room, has
the infection on his feet’.24 Further medical recognition came in May
1929, when three doctors, working at the University of California stu-
dent health service, published data that showed tinea pedis was endemic
amongst students.25 They wrote that many students arrived at college
with the infection: 53% of males and 15% of females, and the incidence
rose to 85% in those ﬁnal year students who took gymnasium classes.
In a follow up study, the doctors showed at the end of their ﬁrst year,
the incidence amongst freshmen had risen from 53% to 78%, but was
only 2% higher in female students.26 The sex differences suggested to
contemporaries four factors in the emergence of tinea pedis: the new
male enthusiasm for using gymnasia, swimming baths and other sports
facilities; the poor facilities for changing and showering at these loca-
tions; male indifference to personal hygiene; and the types of socks and
shoes worn for sport and after, where the lighter, open shoes of women
militated against infection taking hold. Athlete’s foot was also possi-
bly a consequence of public sanitary facilities, where the sexes, social
classes, races and different ages mingled, and where anyone might be a
‘carrier’.
Awareness of the problem grew quickly. The link between tinea pedis
and athletes was evident in 1931 when the Los Angeles Times termed
it the ‘gymnasium malady’.27 In the same year, W. L. Gould, a physi-
cian from Albany, New York State, reported to the United States Public
Health Service that possibly 50% of all adults suffered from tinea pedis
and that its incidence was particularly high in the states bordering the
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Gulf of Mexico and in California, due to heat and humidity.28 At the
1932 Olympic Games in Los Angeles, special antiseptic footbaths were
provided to prevent infection.29 By the mid-1930s there was recogni-
tion that it was not just students and athletes who were vulnerable.
J. H. Swartz wrote of ‘the addiction of our generation to the frequent-
ing of gymnasiums (sic), baths and locker rooms . . . and the tendency to
exercise violently and perspiring in unsterilizable socks and body cloth-
ing’. He went on to wonder if the Romans were similarly affected?30
Dermatologists also saw tinea pedis as threat to the family, through
cross-infection in the home, where baths and showers were becom-
ing more common.31 However, Ayu Majima has shown that ringworm
amongst the poor – even tinea pedis – was never described with the
neologism of athlete’s foot and sufferers remained stigmatised.32
Doctors prescribed a variety of remedies for tinea pedis, but because of
mixed results, their advice was mainly that prevention was better than
cure. Thus, anyone visiting a swimming baths and showering in public
facilities was told to disinfect their feet where possible, to avoid walking
on ﬂoors in bare feet, to dry their feet and toes after bathing, never to
share towels or clothing, and to wash socks at high temperatures. The
main remedies were topical antifungal creams. The standbys were Whit-
ﬁeld’s ointment (the active ingredients were 5% salicylic acid and 3%
benzoic acid in petroleum jelly) and Castellani’s carbol-fuchsin paint.
However, the variable presentation of the condition and its tendency to
chronicity encouraged innovations, both in combinations of remedies
and new chemicals.33 There were many complaints of overtreatment.34
Proprietary medical companies, which already had a signiﬁcance market
with topical antiseptic remedies, seized on the new epidemic, pro-
ducing new products and rebranding older ones as having antifungal
as well as antibacterial properties.35 The most prominently advertised
remedy in newspapers and magazines was a derivative of a veterinary
liniment – ‘Absorbine Jr.’, marketed by W. F. Young, Inc.36 The company
claimed to have coined the term athlete’s foot and in the late 1930s, the
advertisements for Absorbine Jr. echoed public posters against venereal
disease and referred to earlier fears, from the time of Typhoid Mary, to
unrecognised carriers (see Figure 2.1).
Older products for ‘skin disorders of the feet’, such as Dr Scholl’s
‘Solvex’, were rebranded to target the new consumers, thus, its adver-
tisement claimed it was effective against ‘gym or athlete’s foot’, ‘foot
itch’ and ‘golfer’s itch’.37 While doctors promoted the possibilities of
prevention and commercial drug companies sold ‘sure-cure remedies’,
there was also a sense that the high prevalence of tinea pedis meant
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Figure 2.1 ‘ABSORBINE JR.’ Athlete’s foot advertisement, Life, 3(7)16 August
1937, 81. The advertisement is ©2013 DSE Healthcare Solutions, used
under Creative Commons Attribution – Non-commercial licence: http://
creativecommons.org/licenses/by/3.0/
that it was an inevitable consequence of wearing socks and shoes; or, as
it was later put, ‘a penalty of civilization’.38
In Britain there was less medical and public awareness of tinea pedis
and the term athlete’s foot was not widely adopted until the late 1930s.
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Medical writings concentrated on diagnosis and treatment in individual
patients rather than any social group. However, doctors noted that it
was a disease with ‘something of the nature of a social qualiﬁcation,
being commonly met among the upper and middle classes’ and, being
mostly spread through bathing; it was, then ‘paradoxically . . . a penalty
of cleanliness’.39 This changed in the 1940s, when Britain found its
equivalent of American athletes – coal miners. Tinea pedis was iden-
tiﬁed as the commonest cause of miner’s dermatitis, a new condition
resulting, again paradoxically, from the provision of pithead baths for
communal bathing at the end of underground shifts. The Sankey Com-
mission, which had reported on the future of the coal industry in 1919
had recommended measures to improve the health and welfare facili-
ties for miners and the largest proportion of its expenditure (35%) went
on pithead baths.40 Baths were introduced only slowly and the preva-
lence of tinea pedis only gained a national proﬁle during the Second
World War, when absenteeism due to illness and injuries was a threat to
production in a pivotal industry.
Soldiers and miners
Concern about the incidence of tinea pedis amongst military personnel
had been expressed between the wars. A study for the United States Navy
published as early as 1924, showed 13% of all ranks were affected, but
levels were as high as 91% amongst ofﬁcers recruited from college. The
same scenario was reported in the late 1930s in the Royal Navy, with
the condition being prevalent amongst all ranks in tropical stations.
Surgeon-Commander J. C. Souter expressed the opinion that tinea pedis
was a submerged problem, where itching and discomfort was tolerated
by men, ‘yet every sufferer is a potential casualty’ should the condi-
tion worsen, as it might on active duty when changes of clothing were
difﬁcult, or in the tropics.41
During the Second World War, skin diseases were a major cause of
invalidism due to poor skin hygiene in combat locations, communal
washing facilities and exposure to new pathogens.42 In tropical theatres
there were reports that skin conditions were responsible for three quar-
ters of sick bay attendances in the Paciﬁc.43 One response at home was
that in 1943, the Walter Reed Army Medical Centre in Washington
established a mycology laboratory headed by Norman Conant who
had started his career in Botany at Harvard, training with Raymond
Sabouraud in Paris before taking a post in the Department of Micro-
biology at Duke University, specialising in mycology. He had worked on
allergies and tinea, but gained international recognition in 1944 with
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the publication of a Manual of Clinical Mycology, co-authored with D. S.
Martin, D. T. Smith, R. D. Baker and J. L. Callaway, all from Duke’s Med-
ical faculty. There were also problems at home amongst soldiers being
exposed to geographically speciﬁc fungi at training bases in Western and
Midwestern states, which we discuss in the Chapter 4.
However, the highest proﬁle incident with tinea pedis during the war
concerned a treatment on the home front. A mixture of phenol and
camphor was very popular, but there were reports of overtreatment and
high levels of exposure, leading to deaths.44 The remedy was champi-
oned by Paul de Kruif in an article, entitled ‘A Working Cure for Athlete’s
Foot’ in The Reader’s Digest in May 1942.45 De Kruif is best known today
for his book Microbes Hunters and for assisting Sinclair Lewis in the writ-
ing of Arrowsmith, but in the 1920s and 1930s he was a signiﬁcant ﬁgure
in American medicine.46 He had worked for the Rockefeller Institute
and become as publicist for medical science, serving as secretary to the
President’s Commission for Infantile Paralysis in 1934. However, by the
1940s he had become a controversial personality, mainly through publi-
cising various medical innovations, of which his athlete’s foot cure was
seen as another questionable example.47 Indeed, such was de Kruif’s rep-
utation that the FDA issued a public warning against the use of phenol
camphor mixture later in 1942.48
Amongst British forces in South East Asia, the prevalence of all forms
of ringworm was so serious that the Royal Army Medical Corps set
up a research unit there on soldier’s dermatitis. Surveys by unit staff
revealed that amongst soldiers in Malaya and Hong Kong, 79.5% had
tinea pedis and 33.5% had tinea corporis, tinea cruris or all three.49
However, ringworm received most attention in Britain, not because of
its military toll, but due to its incidence in workers at home, along with
the investment in fungus research prompted by the discovery of the
antibiotic properties of penicillin and emerging problem of systemic
mycoses. In Britain, the Medical Research Council (MRC) appointed a
Medical Mycology Committee in 1943.50 One goal was to rationalise
taxonomies and tinea pedis was a particular problem. At the time
the following terms were used by doctors across the Empire: ‘athlete’s
foot’; ‘Hong Kong’, ‘Shanghai’ and ‘Singapore foot’; ‘gym’, ‘golfers’ and
‘swimmers’ itch; ‘toe-rot’; ‘ringworm of the feet’; ‘Cantlie’s foot tetter’,
‘eczematoid ringworm of the extremities’; ‘dermatomycosis’; ‘epider-
momycosis’; and ‘epidermophytosis’.51 Perhaps this variety was further
evidence of the novelty of the infection, or even the diversity of spe-
ciﬁc pathogens producing different types of lesion, but most likely it
reﬂected the multiplicity of practitioners, locations and presentations.
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The Committee’s work during the war focused on coal miners. The
ﬁrst detailed study was made in 1943 by R. B. Knowles in the coal-
ﬁelds of the north Midlands and South Yorkshire. He conﬁrmed the
widely held view that the introduction of pithead baths in the 1920s
and 1930s had created the problem.52 After the nationalisation of the
industry in 1946 and the creation of the National Coal Board (NCB),
surveys and reporting on the welfare of miners increased.53 One study of
miners in Warwickshire in 1946 found that 52% of the men had ‘intra-
digital disease’, 15% had ‘foot lesions other than fungus infection’, and
only 33% had ‘healthy feet’.54 It was against this background that in
November 1951, a Committee on Industrial Epidermophytosis (CIE) was
established within the MRC’s Industrial Health Research Board (IHRB).
The Committee’s membership indicates how tinea pedis had become
a multi-specialist problem. The CIE was chaired by John T. Ingram,
a dermatologist from Leeds, who had considerable experience in the
army and was joined by two other dermatologists, George H. Percival
(Edinburgh) and H. Renwick Vickers (Shefﬁeld).55 Geoffrey C. Ainsworth
provided mycological expertise, D. D. Reid from the London School of
Hygiene and Tropical Medicine dealt with medical statistics, while R. E.
Lane from the University of Manchester provided wider occupational
health expertise.56 Another member was Archibald L. Cochrane, who
was then at the MRC’s Pneumoconiosis Research Unit in Penarth, and
later became a champion of randomised clinical trials, where his legacy
has been institutionalised in the network of Cochrane collaborations.57
Also on the Committee were T. E. Howell, the Principal Medical Inspec-
tor of Mines at the Ministry of Fuel and Power, and J. M. Rogan, Principal
Medical Ofﬁcer at NCB.58
The initial brief was quite wide, but Ingram argued that the CIE should
‘deal in the ﬁrst place especially with epidermophytosis of the feet in
coal miners and to leave all side issues . . .until later’.59 Rogan stressed
the NCB’s economic objectives of reducing absenteeism and other costs,
wanting the CIE to focus on practical measures, such as prevention and
methods for mass treatment.60 However, Ingram had other ideas and fos-
tered work across specialisms in epidemiology, the natural history of the
disease, clinical and mycological diagnosis, research on fungal growth,
the chemistry of the skin and the histopathology of the condition.61
Finding out the nature and scale of the problem in miners was the
priority. Epidemiological studies were commissioned from J. G. Holmes,
a dermatologist in Cardiff, and Jimmy Gentles, a mycologist who, dur-
ing his term of appointment, moved to the University of Glasgow. Early
results came from a pilot that Rogan arranged for Holmes to conduct
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at a colliery in Allerton Bywater, near Leeds.62 There were issues with
compliance and Holmes complained that miners showed a ‘lack of foot-
consciousness, thoughtlessness and in a few cases, selﬁshness’.63 A larger
study of 2,101 men working in mines across the country was published
in 1956.64 Clinical examinations found that 1,900 men (90%) had some
abnormality of the skin of the foot, yet in only 438 cases (21%) was
there laboratory-conﬁrmed fungal infection. However, rates varied, from
50% in one East Midlands pit to 3.5% in the Yorkshire coalﬁeld over-
all. The problems of reconciling clinical and laboratory diagnoses were
shown by the fact that 75 patients ‘showed so-called “diagnostic” lesions
without any evidence of fungus being found’, while 4% of those with
‘clinically normal feet’ tested positive in the laboratory.65
The Medical Mycology Committee’s post-war survey on the incidence
of mycoses in Britain, published in 1948, conﬁrmed a view widely
held within the medical profession, that the incidence of tinea capi-
tis, the new term for ringworm of the scalp, in children had risen during
the war. The rise was attributed to the suspension of X-ray treatment, the
relaxation in school hygiene, and to the evacuation of children, with a
consequent decline in hygiene and greater exposure to cats, dogs and
cattle.66 An increase in tinea pedis in adults was explained by contin-
uing improvements in hygiene, the exposure of men to infection in
military settings, and the circulation of ringworm species around the
world with troop movements.67 A particular concern was the impor-
tation of T. rubrum to Europe from the Far East, as it was one of the
most difﬁcult ringworm species to treat. However, the reported inci-
dence of tinea pedis in Britain was nowhere near that in the United
States. In 1950, Jacqueline Walker reported on a survey of 1,010 army
recruits, 857 of whom were free of infection and of the 123 suspected
cases, only 39 (4%) were conﬁrmed in the laboratory.68 One reason for
the low incidence was the relative paucity of sports and college facilities,
and there were certainly fewer homes with bathrooms where infection
could spread within families. The place where the spread of tinea pedis
was most common was in elite public schools, which had the best sports
facilities.69
One problem in surveys was the discrepancy between clinical and
laboratory diagnoses. Doctors accepted that microscopy and culturing
were more reliable than clinical methods; however, there were few
laboratories available to provide the tests and a reluctance amongst der-
matologists to use them.70 For some, the reliability of laboratory results
was a moot point. They depended on many factors: from the quality of
the skin sample taken, through to the competence of staff in particular
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laboratories. Accuracy mattered more in epidemiological studies than it
did in clinical practice. False positives in a low incidence population
would skew the result signiﬁcantly, whereas dermatologists and gen-
eral practitioners were prescribing broad spectrum, topical fungicides
for all presentations of ‘inter-digital dermatitis’ without laboratory con-
ﬁrmation. Better-targeted treatment would have prevented what one
doctor later termed ‘a chemical assault’ on the feet of the nation in the
post-war era.71
The uncertainties over diagnosis, especially when fungi were found
without clinical disease in ‘symptomless carriers’, reopened the ques-
tion: were the fungi causing tinea pedis external contagious agents
caught from other people, or were they saprophytic parasites of the
skin that only caused disease in certain conditions?72 While patterns
of infection in particular groups and the identiﬁcation of infective fungi
on ﬂoors in baths and showers pointed to the overriding importance
of contagion, some doctors argued that infection was more compli-
cated. The seed and soil analogy was used to suggest both that prior
physico-chemical changes had to make the skin open to infection, as
in pre-pubescent children, or that a ‘factor X’ was involved.73 Such
views were important because doctors were only too aware of the lim-
itations of topical remedies and, hence, were keen to promote speciﬁc
and general preventative measures.
Chemical abuse of the nation’s feet
In the late 1940s, the American market was ﬂooded with topical treat-
ments for athlete’s foot. Writing in JAMA in 1946, G. B. Underwood
and colleagues wrote on the ‘unbelievable chemical abuse’ of the feet of
Americans.74 In their practice they reported:
Feet are seen daily, painted all the colors of the rainbow or daubed
so thick with salves that removal with a tongue blade is necessary
to view the underlying dermatitis. The shoes smell of solution of
formaldehyde and are caked on the inside with fungicidal powders.
The patients, when questioned about the number of remedies used,
shrug their shoulders and exclaim ‘I couldn’t begin to recall. I’ve used
everything. You are the sixth or seventh doctor I have seen. I’ve had
this stuff between my toes for years. Just when I think it is well, it’s
back again. Each time it comes back I try something else. I’ve spent a
small fortune for remedies, and look at my poor feet.’ These patients
are sure of the cause of their dermatitis. It is the ‘athlete’s foot’ or the
‘fungus.’75
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They reproduced examples of the ways that companies selling topical
remedies portrayed athlete’s foot as dire threats to individual and public
health. Potions were said to ‘Kill Athlete’s Foot Germs on Contact’, to
cure ‘Factory Feet’ and warned ‘YOU PROBABLY HAVE ATHLETE’S FOOT
or will get it’. Brands had names like ‘Soretone’, ‘Korium’, ‘Octofen’
and ‘Desitin’. Some remedies were cure-alls, such as ‘3XB’, which also
helped with ‘minor wounds, blisters resulting from ivy poisoning, or
similar conditions, corns, calluses, tired feet, chaﬁng, prickly heat or
similar skin conditions’. Underwood and his colleagues reported anal-
yses of 106 popular remedies, ﬁnding the most common ingredients
were phenol, ethyl aminobenzoate and, most worryingly, mercurial
compounds. The Mennem Company’s leading brand ‘Quinsana’, whose
advertising regularly featured the threat of catching athlete’s foot on the
beach, contained Hydroxy-Quinolene, Magnesium stearate and boric
acid. Underwood and his colleagues ended with a plea to dermatologists
to ‘take steps to prevent the commercial commandeering of scientiﬁc
reports and formulas’, and called for the regulation of popular skin
treatments.
Whether the rash of new products was due to a real increase in the
incidence of fungal skin infections is unclear, but the post-war increase
in tinea capitis in American schools suggests that there was more ring-
worm in communities.76 Infected children were treated with X-rays, as
well as topical remedies and there were calls for public health agen-
cies to take up the matter.77 Laboratory reports showed that the main
cause was no longer Microsporon canis caught from pet and farm animals,
but Microsporon audouini, the main European ringworm species.78 State
and county authorities started campaigns, which were claimed to be
effective. The reported incidence of tinea capitis fell in the 1950s, even
though X-rays, the former treatment of choice, was dropped because of
concern about the long term health effects of exposure to radiation.79
The most notorious example of the enthusiasm for developing and tri-
alling treatments for athlete’s foot were the investigations on prisoners
undertaken by Arthur Kligman in Pennsylvania and discussed in Arthur
M. Hornblum’s book Acres of Skin.80 Kligman worked in the Department
of Dermatology at the University of Pennsylvania Medical School, then
headed by David Pillsbury. Prior to his work with prisoners, Kligman had
made experimental studies of children in mental defective homes to test
the effects of X-rays used to treat tinea capitis.81 He wrote in 1952 that,
The work was carried out at a state institution for congenital mental
defectives . . .The experimental circumstances were ideal in that a
large number of individuals living under conﬁned circumstances
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could be inoculated at will and the course of the disease minutely
studied from its very onset. Biopsy material was freely available.
By contrast, Sabouraud’s researches were largely limited to the clin-
ical opportunities presented by ringworm patients appearing at the
Paris clinic.82
This work was part of wider studies of treatments for ringworm, espe-
cially the new topical creams versus depilation, either mechanically or
by X-rays.83
In 1957, Kligman published an article with John Strauss that opened
with the following statement.
So much has been written about the subject of athlete’s foot that one
can hardly add still another paper to an already mountainous pile
without some justiﬁcation. We thought we could gain some fresh
appreciation of this disease by studying it experimentally in a prison
population. With this group it was possible to do a number of things
which would otherwise have been rather difﬁcult. Rigid control over
the subjects, adult males in the age range of 20–50 years, offered
many experimental advantages.84
Kligman’s research at the prison, which ran from 1951 to 1974, grew
from initial studies of athlete’s foot treatments, to medications for a wide
range of other skin conditions and cosmetics. He worked closely with
pharmaceutical companies and prisoners were paid to be human guinea
pigs. Kligman became infamous because of the ethical status of his trials,
however, in American dermatology he remained a hero, with his death
marked by an article with the by-line ‘Albert the Magniﬁcent’ and no
mention of the criticisms of his work.85 Controversy was fed by the fact
that Kligman was unapologetic; he considered retrospective judgements
of the ethics of his work unfair and that he defended it, arguing that
medicine had beneﬁted and ‘no prisoner suffered long-term harm, as far
as he knew’.86 Nonetheless, the furore caused by criticisms of his work in
the 1970s, including the development of the anti-wrinkle cream Retin-
A, prompted stricter Federal regulations on medical experiments with
prisoners and human subjects more widely.87
In both the United States and Britain, the reported prevalence of
tinea capitis waxed and waned in the 1960s. One clear trend in the
United States was the growing importance of infection with T. tonsurans,
seemingly imported from Central America and the Caribbean, with
M. audouinii seemingly in decline across the northern hemisphere.88
Some dermatologists speculated that the fall in incidence in the late
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1960s was due to the fashion for long hair in both men and women, and
for ‘Afros’ amongst African-Americans, both being protective against
hair root infection.89
Griseofulvin: ‘Epoch making’ antifungal treatment
From the early 1940s, state and pharmaceutical company laboratories
sought novel approaches to fungal infections following the model of
antibiotics with bacteria; that is, chemicals that could be injected or
taken orally, that would act as ‘magic bullets’, affecting the pathogenic
microorganism and not the host’s cells. There had been hopes in the
early 1940s that penicillin, or similar fungally derived products, would
be antagonist to pathogenic fungi, but these were unfulﬁlled. Nonethe-
less, the treatment of fungal infections did beneﬁt from the increase
in the scale and intensity of biomedical and pharmaceutical research.90
Nystatin, which we discuss in Chapter 3, introduced in the early 1950s,
was the only success in the search for antifungal antibiotics for a decade;
but it was ineffective against ringworm and could not be taken orally.
Researchers turned to other approaches. One was to build upon the
observation that vulnerability to tinea capitis seemed to end at puberty,
which pointed to changes to the chemistry of hair follicles and the iden-
tiﬁcation of heavy fatty acids that seemed to have antifungal properties.
The most important was undecylenic acid and its salts.91 The effective-
ness of this fatty acid was similar to compounds already in use, but it had
the advantage, allegedly, of being less irritant because it was ‘natural’.
In Britain, the following proprietary preparations that were widely used
from the late 1940s, all contained zinc undecylenate: ‘Tineax’ from Bur-
roughs Wellcome and Co.; ‘Mycota’ from Boots and ‘Desenex’ from
Wallace and Tierman. The salts of two other fatty acids, proprionic and
caprylic, were also used in the same way. The market leader in Britain
was ‘Mycil’, produced by British Drug Houses (BDH). Its active substance
was p-chlorophenyl-a-glycerol ether, marketed as ‘chlorphenesin’ and
discovered in 1947 by Frank Hartley, then Research Director at BDH, in
1947.92 In the United States, ‘Desenex’ ointment and foot powder, pro-
duced by Wallace and Tiernan, led the way, and were used in the Korean
War and later enjoyed endorsement from celebrities from the National
Football League, such as Johnny Unitas.
An editorial in the Lancet in July 1946 had wryly observed that
most doctors ‘take a personal interest in tinea pedis, for – like piles,
toothache, and sore throats – if we manage to escape it ourselves, it
will not be long before some member of our family is clamouring for
attention’.93 The editorial bemoaned the fact that, despite the ﬂood of
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new remedies, most treatments had limited effectiveness, particularly in
the longer term. Over a decade later, reviewing treatments for general
practitioners in May 1958, Grant Peterkin, head of the Skin Department
at the Edinburgh Royal Inﬁrmary, reﬂected that old favourites, such as
Whitﬁeld’s ointment and Lassar’s paste, were still second to none.94 He
noted the recent impact of nystatin on the treatment of Candida infec-
tions, both in topical applications and when taken orally for intestinal
infection, and regretted that there had been no similar advance with
tinea pedis. However, he was hopeful: ‘Yet it seems possible that in the
future fungus infections of the skin may be eradicated by some antibi-
otic given parenterally [orally].’95 By the end of the year his hope had
been fulﬁlled with the announcement of the oral antifungal drug –
griseofulvin.96
Griseofulvin had been ﬁrst isolated from the fungus Penicillium griseo-
fulvum by Harold Raistrick at the London School of Hygiene and Tropical
Medicine (LSHTM) in 1939.97 Raistrick was Britain’s leading ﬁgure in the
biochemistry of fungi, having worked on industrial fermentation for
the government in the First World War and then for Imperial Chemi-
cal Industries (ICI), before his appointment to the LSHTM in 1929. He
had worked on penicillin in the early 1930s, following up Alexander
Fleming’s early publications, and his laboratory had continued to use
Penicillium spp. as experimental models.98 Surprisingly perhaps, griseo-
fulvin was not screened for antibiotic properties in the early 1940s and
its antifungal potential was only recognised at the end of the decade,
and then in an agricultural rather than medical context.
Researchers at the Butterwick Research Laboratories of ICI found that
it produced ‘curling’ in the hyphae of certain fungal species, inhibit-
ing cell wall formation and cell division.99 Further work showed it to be
an effective, broad spectrum fungicide, though it had no great advan-
tage over existing and cheaper commercial compounds. Mycologists
remained interested in the compound, as did researchers at Glaxo’s
Sefton Park and ICI’s Alderley Park Laboratories. Parallel, but separate,
investigations showed that griseofulvin had a low toxicity when high
doses were given to experimental animals. It also proved to be valuable
as a laboratory agent for inhibiting the growth of hyphae-forming fungi,
even at quite low concentrations.100 However, its potential as an oral
antifungal seemed limited because it was largely insoluble in water and,
hence, could not be made available for absorption through the gut.101
Griseofulvin’s promise as a fungicide in agriculture led Glaxo
researchers to test its toxicity to humans to determine safe exposures for
farm workers.102 These trials showed few, if any, toxic effects. However,
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commercial development was not fast-tracked because griseofulvin was
expensive to produce. In the mid-1950s, Glaxo researchers learnt that
two other groups were interested in griseofulvin: Gentles through his
work for the NCB, and workers at ICI who were exploring veterinary
and human uses. Both Glaxo and ICI had taken out provisional patents
on different aspects of the production and use of griseofulvin, and in an
unusual move, signed a joint agreement in the spring of 1957 on their
respective rights in all areas, from patents through to licensing. Glaxo
continued to work with Gentles on animal studies, which led to a pub-
lication in Nature in August 1958.103 However, work at ICI showed that
griseofulvin could affect mammalian cell division and this prompted
further collaboration between researchers in both companies.104 In com-
paring data, it seemed that the different results were due to the particle
size and that the coarser Glaxo compound was safer. Three dermatolo-
gists approached Glaxo for samples to test in patients with ringworm:
Gustav Riehl in Vienna, Harvey Blank in Miami and David Williams at
King’s College London. The ﬁrst results from these clinics were presented
in late 1958.105
David Williams and colleagues published a report of nine patients
with T. rubrum infection who had been successfully treated with orally
administered griseofulvin, supplied by Glaxo.106 There was great excite-
ment about the work. Williams concluded his article with the claim that
griseofulvin ‘represents a fundamentally new therapeutic approach’.107
One Cambridge dermatologist, hearing of the development, had written
to the MRC claiming that the work was ‘epoch making’.108 The London
trial had followed on from a report in August 1958, by Gentles, of suc-
cessful oral treatment of ringworm in experimentally infected guinea
pigs.109 Gentles had rushed to publish and was similarly excited; though
he went for understatement, ending with the remark that this work ‘may
be of some important for future progress in this hitherto unrewarding
ﬁeld of investigation’.110
Gentles and Williams spoke on griseofulvin at the annual meeting
of the British Dermatological Society in July 1959.111 Gentles reviewed
the clinical literature and the growing consensus that it was effective
for two reasons: ﬁrst, through its deposition in keratin (the structural
protein of hair and nails), and second in being fungistatic, that is,
inhibiting the growth of the fungus. This meant that it was likely to
be effective in deep-rooted infections of the hair follicles and in toe-
nails. David Williams began his talk by reﬂecting on the reputation of
dermatology within the medical profession and how this might have to
change.
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Once upon a time – and thus all good stories begin – there was an
old retired general practitioner who said that he could treat all skin
diseases although he could diagnose none. Those were the slap happy
days when local treatment was a magniﬁcent pseudo-science – not
even now do we have much understanding of how local applications
work – and internal treatment was a desperate matter of letting justice
seem to be done, not too critically . . . . But in the last ﬁfteen years
there have been remarkable advances in the chemical and antibiotic
ﬁeld. Treatment is becoming so speciﬁc that there is much to be said
for a proper diagnosis before starting it. Penicillin has made syphilis
so rare that it is easy to forget its existence. Anti-tuberculous drugs
have ruined for us a fascinating, a lovely group of dermatological
conditions. And now griseofulvin.112
Williams stated that in his clinic the ‘experience so far has been so
gratifying that it is difﬁcult to be restrained about what seems to be
happening’. He gave the drug a ringing endorsement, stating ‘griseoful-
vin is a remarkable drug with minimal toxic effects and that it has come
to stay, we have no doubt’.113 Questions remained about dosage, resis-
tance, re-infection and toxicity, yet in a call-to-arms, he concluded, ‘As
Montgomery must have said, the break-through has been achieved and
our forces can now pour through the gap to consolidate our gains.’114
Harvey Blank, who worked at the University of Miami School of
Medicine, had also been prompted by Gentles’s article to obtain griseo-
fulvin from Glaxo.115 He ﬁrst tried it on ‘a desperate and unique case’ of
T. rubrum infection, with some success, before a more organised trial on
31 patients with various forms of ringworm. The results were ‘uniformly
favorable’, though he cautioned that toxicity still needed to be tested
with prolonged use, and that it was too early to say anything about
the likelihood of relapses. Nonetheless, the drug was cleared for use in
the United States in July 1959, less than a year after Gentles’s paper
had been published.116 Blank organised a symposium on griseofulvin
in Miami in October 1959, funded by McNeil Laboratories, a subsidiary
of Johnson and Johnson, at which 37 papers were given by speakers
from 11 countries, including Gentles and Williams. The rapid spread
and trialling of the drug indicates the intense medical interest, across so
many countries, that there was in ﬁnding oral antifungal drugs. Intro-
ducing the proceedings in Archives of Dermatology in May 1960, Blank
reﬂected that the development of griseofulvin ‘appears to be assuming
the proportions of an historical nature’.117 A key factor in the enthu-
siastic response in the United States was to explore the potential of
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the drug to treat persistent infection, such as fungal nail infection –
onychomycosis.118
The St John’s Hospital Dermatological Society organised a British
meeting on griseofulvin in May 1960, attended by 189 doctors and
scientists, with 24 papers published in a special issue of the Society’s
Transactions.119 It was already clear that the drug was being widely used
in general practice, as well as in dermatological clinics, and this despite
the fact that it was expensive.120 The introduction to the volume drew
parallels between the ten-year lag in recognising the therapeutic poten-
tial of penicillin, with the 20 years taken from Raistrick’s isolation of
griseofulvin to its ﬁrst clinical use.121 The meeting heard a report of
the ﬁrst controlled clinical trial, led by Brian Russell at St John’s Hos-
pital, which was about to be published in the Lancet.122 The trial showed
griseofulvin was ‘a striking effective remedy’ and that ‘In retrospect, it
is questionable whether a double-blind trial was necessary.’ There were
64 patients in the study: just one person of the 31 receiving the drug
showed no clinical improvement, whereas 30 out 34 patients given the
placebo were ‘unimproved’. However, the study showed that the drug
was no cure-all. There was considerable variation in the responses of
individuals and even the toes of the same person! In addition, when lab-
oratory rather than clinical assessments of cures were used, things were
less positive still. Thus, after many weeks and months of treatment, over
half of patients continued to harbour the fungus in the skin between
their toes, and 26 of 32 patients had some abnormality in their nails. The
redeeming feature was that no side-effects were reported; hence, the very
long-term treatments that seemed to be necessary were felt to be safe.
Summing up at the St John’s Symposium, Brian Russell stated that
griseofulvin should be the treatment of choice for all forms of tinea capi-
tis, except that due to M. canis, and, disappointingly, tinea pedis due to
T. rubrum.123 The drug was also recommended for other types of ring-
worm and favus, but was said to be only moderately effective against
animal ringworm species. Interestingly, its value was ‘doubtful or occa-
sional’ against the species that had been the main cause tinea pedis in
earlier decades: T. interdigitale, T. mentagophytes and E. ﬂoccosum. Russell
emphasised again that griseofulvin was fungistatic and not fungicidal,
hence, ‘clinical clearance is not synonymous with cure’, while ‘myco-
logical clearance’, if it could be achieved at all, took much longer. He
also pointed to issues with re-infection, carriers, immunological effects,
and its impact on the ecology of the body, responding to some reports
that griseofulvin opened the body to Candida infections.
Griseofulvin became available as a prescription drug in Britain in April
1959; marketed as ‘Grisovin’ by Glaxo and ‘Fulcin’ by ICI.124 There was
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no expectation within Glaxo that griseofulvin would be another peni-
cillin in terms of sales and proﬁt. Hector Walker, the head of research
and development, observed, ‘Dermatologists – at least some of them –
seem a little bit disturbed that a speciﬁc treatment is now available that
represents a not unsizeable part of their total practice, and there are reac-
tionary dermatologists just as there are physicians when new treatments
appear.’125 The expectation was that topical treatments for ringworm
would continue to be preferred, with griseofulvin used for persistent
infection and onychomycosis. Soon, even these qualiﬁed hopes were
being moderated. An editorial in Lancet mocked the recent meetings on
the drug.
Massed choirs met at international symposia in Miami last October
and in London under the wing of the St. John’s Hospital Dermato-
logical Society on May 13 and 14 to add their paeans of praise. They
sang, for doctors, in surprisingly close harmony. The main theme has
been the remarkable success of griseofulvin, with pitch according to
skill and experience. More recent variations have wandered a little
into the more pensive, minor keys as certain problems and failures
have become evident.126
Two years later, there was another sceptical editorial, this time respond-
ing to an epidemiological study of tinea pedis by Mary English that
showed that only a small proportion of lesions of the toe-webs were
fungal in origin and that there very few healthy carriers.127
Griseofulvin has not lived up to expectations, and often does not
eliminate fungus from the feet. In acute cases, topical fungicides
often do more harm than good . . . For chronic cases, Whitﬁeld’s oint-
ment is still the most usual remedy, and some difﬁcult cases are kept
symptom free by wearing sandals.128
However, Glaxo had been working on the drug with its American
licensees and in 1962 developed ﬁne particle form – GRISOVIN FP – for
clinical trials. This was better absorbed through the gut, giving more
even blood levels of the drug, even at half of the previously recom-
mended dose. Nonetheless, results were still mixed and worries about
toxicity remained.129
Despite the problems, in the 1960s griseofulvin became a stan-
dard treatment for susceptible forms of ringworm and joined nystatin
in the new armoury of antifungal antibiotics.130 Research on this
class of drugs burgeoned in the decade, as mycological researchers in
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universities, government laboratories and pharmaceutical companies
joined the search for natural and synthesised compounds with similar
properties.131 In the wake of the thalidomide scandal and the intro-
duction of stricter safety regulations, much of the further work on
griseofulvin was on its toxicity.132 However, while many side effects
were identiﬁed, they were all either relatively minor (headaches, gastro-
intestinal, photosensitivity, liver function, allergic reaction), or cleared
up after treatment ended. Griseofulvin was given prophylactically to
American troops in Vietnam, though this did not stop ringworm being
a major cause of disability.133 Only reduced exposure, in shorter combat
rotations, affected the overall incidence of ringworm and relapses were
blamed on poor compliance in prolonged treatment.134
Griseofulvin, as a treatment for most forms of ringworm, united ath-
lete’s foot with other sites of infection, such that tinea pedis became
distanced from hygiene and ﬁtness. This shift exempliﬁed a trend in
medicine from the late nineteenth century of moving deﬁnitions of
infections based on symptoms to speciﬁc causes. Ringworm was not uni-
ﬁed by a speciﬁc cause, because there were many fungal pathogens, but
rather by a treatment – griseofulvin. The drug was a major contributor to
athlete’s foot and other forms of ringworm, becoming deﬁned as types
of ‘dermatophytosis’, a term which grew in popularity from the 1960s.
It was in fact a quite general, hybrid causal-symptomatic deﬁnition,
literally, skin infection with fungi.
Azoles: ‘A major advance in medical mycology’135
The success of griseofulvin, more than the earlier nystatin for can-
didiasis, changed the prospects of antifungal therapy and further new
drugs were anticipated.136 In the event, a widely adopted, oral antifun-
gal alternative to griseofulvin for dermatophytosis did not emerge for
nearly 20 years, until in 1977 the Belgian company Janssen announced
ketoconazole.137 Branded as ‘Nizoral’, it was one of the group of syn-
thetic compounds called ‘imidazoles’, or more generally ‘azoles’, that
the company had been screening since the late 1960s. The ﬁrst two
widely used drugs from this work were announced in 1969: clotrima-
zole from Bayer and miconazole, also from Bayer, which were targeted at
Candida infection and deep seated systemic mycoses. Ketoconazole was
different. It was promoted as a broad spectrum antifungal that could be
used to treat dermatophytosis as well as candidiasis, histoplasmosis and
cryptococcosis.138
Following the precedent of griseofulvin, Janssen sponsored a meet-
ing to review progress and spread the word. The ﬁrst international
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symposium on ketoconazole was held in Medellin in Columbia in
November 1979, linked to the Ninth Ibero-Latin American Dermatol-
ogy Congress.139 The participants concluded that they were at ‘the
threshold of an important new advance’ and that ketoconazole was
the orally administered drug that was effective for a range of condi-
tions, from acute systemic mycosis through to the growing problem of
onychomycosis, that clinicians had been looking for.140 The drug had
been developed by researchers at Janssen Laboratories from the modiﬁ-
cation of miconazole, which they made less toxic and more suitable for
oral administration.141 The new drug was effective against many of the
regionally speciﬁc fungal infections discussed in the next chapter and
with immunocompromised patients. The concluding address was given
by William Dismukes, who worked at the University of Alabama School
of Medicine in Birmingham and was a founding member of the newly
formed, NIH funded, Mycoses Study Group. He hoped that ketocona-
zole would be ‘the ﬁrst “total” antifungal agent with a broad spectrum
of activity’ and that very promising results in vitro and early clinical trials
now needed to followed by longer term studies.142
The question with ringworm was this, was ketoconazole more effec-
tive than griseofulvin? Two reports by clinicians were presented at
Medellin, one from Oregon in the United States and other Mexico. The
group from Oregon reﬂected that,
During more than 20 years of clinical experience with griseofulvin,
the subject of failure of therapy has received scant notice. Only rarely
do patients fail to respond to this drug because of either resistance of
the organism or inadequate tissue levels of griseofulvin. Much more
commonly, dermatophytoses respond to the drug but then either fail
to clear or recur soon after discontinuance of therapy.143
The conclusion of the Oregon study was that ketoconazole was effec-
tive in cases that did not respond to griseofulvin, but whether it should
be the ﬁrst choice was left open. The second report was similarly posi-
tive. Ketoconazole was approved for clinical use and became available in
1982. The results of comparative trials with griseofulvin were published
in 1985, which found they were equally effective for hair, skin and nail
infection.144 On balance, griseofulvin remained the ﬁrst choice therapy
because of concerns about liver toxicity of ketoconazole, which was
recommended for patients who were griseofulvin-intolerant.145 In the
1990s, two new, broad spectrum remedies that could be used topi-
cally and given orally became available for ringworm: itraconazole,
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another triazole developed by Janssen and marketed as Sporanox; and
terbinaﬁne developed by Novartis and marketed as Lamisil. Thus, the
options available to doctors for treatment at all sites, and with all types
of infection increased. However, there was some evidence of the devel-
opment of drug resistance and tinea pedis increasingly presented along
with the more difﬁcult to treat, onychomycosis. Many of the azole com-
pounds, when patent protection lapsed, became available for topical use
in over-the-counter creams, competing with every other post-war anti-
fungal back to nystatin. The development of azole drugs consolidated
the remaking of athlete’s foot as another type of dermatophytosis.
In this chapter, we have charted the rise and fall of athlete’s foot as
a disease of ﬁtness and hygiene. It is not clear if the reported rise in
incidence in the 1920s was due to the greater awareness, or presence
of new pathogens in Western populations, or new conditions for ring-
worm fungi to spread and ﬂourish. At the time, the majority of doctors
maintained the latter and, speciﬁcally, that ringworm of the feet was
a ‘penalty of civilisation’. In all contexts, medical and public concern
was linked to new lifestyles, new clothing, new military conditions or
new working environments, the latter especially so in Britain, where
coal miners rather than athletes put the condition on the map. While
medical advice initially stressed prevention over treatment, proprietary
medicine manufacturers turned the full weight of product development
and promotion on the condition, typically selling their wares as prod-
ucts of medical progress. Athlete’s foot was also at the forefront of the
antibiotic revolution with fungal infections, through the development
of griseofulvin, coincidentally a compound derived from a species of the
Penicillia. The arrival of griseofulvin and then in the 1970s of the azoles,
accelerated the redesignation of athlete’s foot and other ringworm infec-
tions as dermatophytoses. They were no longer framed as ‘diseases of
modernity’, but as fungal infections that were conquerable, if not yet
fully conquered, by medical progress.
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